

Megachem Limited

20 June 2022

BUY (Maintained)

BBG	MGCM SP
Market cap	S\$62.7m
Price (20 June 2022)	S\$0.47
52-week range	\$\$0.36 - \$\$0.50
Target Price	S\$0.58
Shares Outstanding	133.3m
Free Float	15.1%
Major Shareholders	Chew Choon Tee (35.7%) Chori Co Ltd (30.0%) Tan Bock Chia (19.1%)

P/BV (12/21)	1.0x
Net Debt to EBITDA (12/20)	1.8x

Source: Company data, Bloomberg, SAC Capital

Analyst

Lam Wang Kwan lamwk@saccapital.com.sg

FY22 could be another record year

FY22E is turning out to be another record year for Megachem, after 51.4% gain in net profit in FY21. We are raising our FY22E net earnings estimates by 6.7%, to reflect higher ASP for specialty chemicals and improved margins. We expect FY22E net profit to grow by 2.6% yoy, or 11.7% if non-recurring government grants received in FY21 were excluded. The higher ASP for specialty chemicals is driven by higher upstream crude oil and petrochemical prices. From Jan-Apr 2022, price of crude had risen 58%, and petrochemical prices were up 14%, according to ICIS Petrochemical Index. Singapore's chemical export prices rose 6% in the first four months of 2022.

Major chemical distributors have reported strong 1Q22 improvement in revenue and operating income. Revenue of PT Lautan Luas, a commodity chemical distributor, surged +40.9% yoy and +10.2% qoq, with operating income +89.7% yoy and +2.7% qoq. Brenntag reported sales gain of +44.7% yoy and +12.1% qoq, with bigger gain in operating EBITDA by +54.2% yoy and +33.7% qoq.

What has changed? Supply chain disruption and demand uncertainty have caused Megachem's customers to rethink their strategy for raw material procurement. Instead of bulk purchases and hold stock, they are looking to suppliers with a diversified geographical network that can deliver goods on short notice and in smaller quantity. Megachem's global network of warehouses and logistic supply bases in 11 countries is a competitive edge.

EU nations have agreed on cuts in oil imports from Russia, which will reduce to 10-11% of its current level. The EU has also committed to reduce gas imports by two-thirds within a year. Ireland, Germany and Switzerland are amongst the top five chemical producing countries in the world. Disruption in oil and gas supply could negatively impact chemical exports out of EU, till the EU chemical producers find substitutes for the Russian imports. Customers could turn to specialty chemicals supply from Asia. About 55% of Megachem's sales are to the ASEAN markets, 13% to Europe, and 12% to North Asia.

Maintain BUY at TP of S\$0.58. Our revised FY22E and FY23E are premised on a 3% rise in chemical prices in FY22E and a 1% decline in FY23E, on weaker macro-economic environment in FY23. Gross margin in FY22E is expected to widen by 0.6% pt to 25.2%, aided by inventory stockpiled at end 2021. On the other hand, working capital needs have risen with higher input costs. Strong US\$ vs regional currencies pose some forex risks, as raw material procurement are in US\$, while sales to countries such as Indonesia, China and Vietnam are settled in the local currencies. Our DCF-derived TP is maintained at \$\$0.58 (COE: 12%). BUY.

YE 31 Dec (\$\$m)	FY19A	FY20A	FY21A	FY22E	FY23E
Revenue	113.8	105.2	138.9	145.9	148.8
EBIT	4.9	5.1	8.4	9.2	9.0
Net profit	3.8	5.1	7.8	8.0	7.8
EPS (S cents)	2.88	3.85	5.82	6.00	5.87
DPS (S cents)	1.50	1.50	2.00	2.00	2.00
Net cash / (debt)	(3.5)	(3.1)	(17.4)	(15.5)	(13.0)
Valuation					
EBIT margin (%)	4.3	4.8	6.0	6.3	6.0
ROIC (%)	7.8	7.5	12.0	12.1	11.3
EV/EBITDA (x)	10.8	10.4	8.4	7.4	7.3
P/E (x)	16.3	12.2	8.1	7.8	8.0
Dividend yield (%)	3.2	3.2	4.3	4.3	4.3



Income Statement

FYE 31 Dec (S\$m)	FY19	FY20	FY21	FY22E	FY23E
Revenue	113.8	105.2	138.9	145.9	148.8
Cost of sales	(85.6)	(78.7)	(104.8)	(109.2)	(111.5)
Gross profit	28.2	26.5	34.1	36.8	37.4
Other income	0.6	1.9	1.1	0.6	0.4
Distribution cost	(15.5)	(14.9)	(17.6)	(18.7)	(19.4)
Administrative expenses	(5.5)	(5.7)	(6.3)	(6.5)	(6.5)
Other expenses	(2.9)	(2.8)	(3.0)	(3.0)	(3.0)
Share of profit of joint venture	1.1	1.6	1.6	1.8	1.8
Finance expenses	(1.0)	(0.7)	(8.0)	(1.1)	(1.1)
Profit before tax	5.0	5.9	9.2	9.9	9.7
Income tax expense	(1.0)	(0.7)	(1.2)	(1.7)	(1.6)
Profit for the year	4.0	5.3	8.0	8.2	8.0
Profit/(loss) attributable to:					
Owners of the Company	3.8	5.1	7.8	8.0	7.8
Non-controlling interests	0.1	0.1	0.2	0.2	0.2
Basic and diluted earnings per share (S\$ cents)	2.88	3.85	5.82	6.00	5.87

Cash Flow

FYE 31 Dec (S\$m)	FY19	FY20	FY21	FY22E	FY23E
Profit before tax	5.0	5.9	9.2	9.9	9.7
Depreciation and amortisation	1.3	1.3	1.2	1.4	1.4
Associates & JV	(1.1)	(1.6)	(1.6)	(1.8)	(1.8)
Net finance expense	1.0	0.7	8.0	1.1	1.1
Non-fund items	0.1	(0.0)	(0.0)	-	-
Working capital changes	1.5	0.6	(16.5)	(1.8)	(1.1)
Interest paid	(0.9)	(0.6)	(0.6)	(1.1)	(1.1)
Dividend income	(0.0)	(0.0)	(0.0)	-	-
Tax paid	(1.1)	(8.0)	(0.9)	(1.7)	(1.6)
Operating cash flow	5.7	5.5	(8.4)	5.9	6.6
Capex	(0.5)	(2.8)	(3.5)	(1.3)	(1.3)
Net investments	0.7	0.4	0.6	-	-
Fixed assets disposal	0.0	0.0	0.0	-	-
Others	-	-	-	-	-
Investing cash flow	0.3	(2.4)	(2.8)	(1.3)	(1.3)
Free cash flow	6.0	3.1	(11.2)	4.6	5.3
Dividend paid	(1.8)	(2.1)	(2.4)	(2.8)	(2.8)
Borrowings	(1.4)	(0.1)	8.8	-	-
Equity	-	-	-	-	-
Financing cash flow	(3.2)	(2.2)	6.4	(2.8)	(2.8)
Net change	2.7	1.0	(4.8)	1.9	2.5

Balance Sheet

FYE 31 Dec (S\$m)	FY19	FY20	FY21	FY22E	FY23E
Cash and bank balances	14.9	16.2	11.5	13.4	15.9
Financial Assets	0.2	0.4	0.6	0.6	0.6
Trade and Other Receivable	22.9	24.2	31.1	32.0	32.6
Inventories	25.4	24.4	36.5	35.9	36.7
Others	2.4	2.5	4.5	4.5	4.5
Total current assets	65.9	67.7	84.2	86.4	90.3
PPE	10.3	12.7	15.2	15.3	15.3
ROU assets	2.8	2.7	2.8	2.7	2.5
Investment in associate	6.6	7.6	8.0	9.7	11.5
Others	0.5	0.7	0.7	0.7	0.7
Total non-current assets	20.2	23.6	26.7	28.4	30.1
Total assets	86.2	91.3	110.9	114.8	120.4
Bank Borrowings	17.6	16.8	27.5	27.5	27.5
Trade and Other Payables	12.1	13.5	18.0	16.4	16.8
Finance leases	0.3	0.2	0.4	0.4	0.4
Others	0.3	0.4	0.6	0.6	0.6
Total current liabilities	30.3	30.9	46.5	45.0	45.3
Bank Borrowings	0.9	2.6	1.4	1.4	1.4
Others	2.6	2.6	2.6	2.6	2.6
Total non-current liabilities	3.4	5.1	4.0	4.0	4.0
Share capital	15.9	15.9	15.9	15.9	15.9
Reserves	(3.9)	(4.2)	(4.7)	(4.7)	(4.7)
Retained earnings	37.6	40.7	46.1	51.4	56.6
Equity attributable to owners of the Company	49.6	52.4	57.3	62.6	67.8
Non-controlling interests	2.8	2.9	3.1	3.2	3.3
	52.4	55.3	60.4	65.8	ა.ა 71.1
Total equity	32.4	55.3	60.4	63.8	71.1
Total equity and liabilities	86.2	91.3	110.9	114.8	120.4

Ratios

FYE 31 Dec	FY19	FY20	FY21	FY22E	FY23E
Profitability (%)					
Gross margin	24.8	25.2	24.6	25.2	25.1
EBIT margin	4.3	4.8	6.0	6.3	6.0
Liquidity (x)					
Current ratio	2.0	1.9	1.7	1.8	1.8
Net Debt/EBITDA	0.6	0.5	1.8	1.5	1.3
Interest coverage ratio	6.0	8.7	11.9	9.8	9.7
Net Debt to Equity (%)	6.8	5.7	28.8	23.6	18.3
Valuation (x)					
P/E	16.3	12.2	8.1	7.8	8.0
P/B	1.2	1.1	1.0	1.0	0.9
EV/EBITDA	10.8	10.4	8.4	7.4	7.3
Cash Conversion Cycle					
Trade receivable days	110	115	106	120	120
Inventory days	75	82	73	80	80
Trade payable days	52	60	55	55	55



DISCLAIMERS AND DISCLOSURES

This report has been prepared and distributed by SAC Capital Private Limited ("SAC Capital") which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report has been prepared for the purpose of general circulation, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons and does not purport to be comprehensive or contain all necessary information which a prospective investor may require in arriving at an investment decision. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities. This report is confidential and the information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Capital. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

Whereas SAC Capital has not independently verified all the information set out in this report, all reasonable care and effort has been taken to ensure that the facts stated herein are accurate, this report might contain certain forward looking statements and forward looking financial information which are based on certain assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of the subject company to be materially different from those expressed herein. Predictions, projections or forecasts of the economy or market trends are not indicative of the future performance of the subject company. The inclusion of such statements and information should not be regarded as a representation, warranty or prediction with respect to the accuracy of the underlying assumptions of the subject company or that the forecast results will or are likely to be achieved.

Our opinion and facts set out in this report are based on the market, economic, industry and other applicable conditions prevailing as at the date of the preparation of this report. Such conditions may change significantly over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report, that may or may not have affected our opinion contained herein.

This report contains forward-looking statement which are based on assumptions or forecasts and are subject to uncertainties which may result in the actual result or performance to be materially different from the opinion or facts set out herein. Caution should be exercised in placing undue reliance on such statements. such assumptions or forecasts may change over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report.

No representation or warranty, expressed or implied, is made and no responsibility is accepted by the company, SAC Capital, or any of their affiliates, advisers or representatives as to the fairness, accuracy, completeness or adequacy of such information or facts, in this report or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

SAC Capital and its associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance and/or capital markets related services for the company whose securities are covered in the report. SAC Capital and its related companies may from time to time perform advisory services or solicit such advisory services from the entity mentioned in this report ("Other Services"). This report is therefore classified as a non-independent report. However, the research professionals involved in the preparation of this report are independent of those possible or actual business relationships as they have not and will not participate in the solicitation or provision of such business.

As at the date of this report, SAC Capital does not have proprietary positions or interests in the subject company, except for:

Party	Quantum of position
Nil	Nil

As at the date of this report, SAC Capital, has had business relations with the subject company within the past 12 months, as disclosed hereunder:

Nature of Business Relation	Date of Business Relation
Catalist Sponsorship	Continuing



As at the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

Analyst name	Quantum of position
Nil	Nil

For services rendered in the production and distribution of this Research report, SAC Capital will receive monetary compensation payable by the subject company. The quantum of which was pre-determined prior to the writing and publication of the report and is not dependent on or affected by the recommendation made herein. The future performance of the security will not have a bearing on compensation payable for the purpose of the production of this report either.

ANALYST CERTIFICATION/REGULATION AC

As noted above, research analyst(s) of SAC Capital who produced this report hereby certify that

- (i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);
- (ii) The report was produced independently by him/her;
- (iii) He/she does not on behalf of SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and
- (iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.